Itraconazole is an oral antifungal that has a been reported to have anticancer effect in non-
small cell lung cancer (NSCLC) through inhibition of angiogenesis. The aim is to evaluate …

The antiangiogenic agent bevacizumab has been approved for the treatment of non–small
cell lung cancer (NSCLC), although the survival benefit associated with this agent is …

Introduction Preclinical studies have suggested that the oral antifungal agent itraconazole
specifically inhibits proliferation, migration, and tube formation of endothelial cells …

Purpose: Itraconazole has been repurposed as an anticancer therapeutic agent for multiple
malignancies. In preclinical models, itraconazole has antiangiogenic properties and inhibits …

Background: Carboxyamidotriazole (CAI), a calcium channel blocker, inhibits tumor cell
proliferation, metastasis, and angiogenesis. This trial aimed to determine whether CAI …

Aims and Background First-line chemotherapies for advanced non-small-cell lung cancer
(NSCLC) are platinum-based regimens. An analysis of efficacy outcomes has not yet been …

Itraconazole, a common anti-fungal agent, has demonstrated potential anticancer activity,
including reversing chemoresistance mediated by P-glycoprotein, modulating the signal …

Introduction: Recombinant human endostatin is a novel inhibitor of tumor angiogenesis that
acts specifically on neovascular endothelial cells. Studies have shown that endostar plus …

Understanding cancer biology and the development of novel agents for cancer treatment
has always been the goal of cancer researchers. However, the research and development of …

7552 Background: In 2010, the results of the LETS study demonstrated noninferiority for
overall survival (OS) less than a predefined stopping boundary at the preplanned interim …